Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

NCT06349317 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib

Sponsor

Yongyi Zeng